White Coat Hypertension and Cardiovascular Diseases: Innocent or Guilty

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2018 Mar 10

PMID 29520630

Citations 10

Authors

Mehran Abolbashari

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review aims to clarify the cardiovascular risk of white coat hypertension (WCH).

Recent Findings: Cardiovascular risk of WCH has been evaluated in multiple meta-analyses and population-based studies. International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes study evaluated the cardiovascular risk in 653 patients with WCH and 5137 normotensive patients. The patients were age-matched and were followed for 10.6 years. The results revealed no increased cardiovascular risk except in older high-risk WCH patients. A recent meta-analysis evaluated the cardiovascular risk in WCH subjects without any antihypertensive treatment (23 cohorts, 20 445 individuals), WCH subjects with antihypertensive treatment (11 cohorts, 8656 individuals), and mixed population including both treated and untreated subjects (12 cohorts, 21 336 individuals). This study revealed increased cardiovascular risk in untreated and mixed population WCH subjects but not in treated WCH subjects. WCH might have prognostic impact on cardiovascular outcomes; however, this is not true in all WCH subjects. Further studies should identify the subgroups of WCH that are at increased risk and evaluate the effect of therapeutic measures on cardiovascular outcomes.

Citing Articles

A Metric Shedding Light on the Relationship Between White Coat Hypertension and Anxiety: The Hospital Anxiety and Depression Scale-Anxiety.

Guler Y, Genc O, Yildirim A, Halil U, Capar G, Ozdogan C Anatol J Cardiol. 2024; .

PMID: 39475171 PMC: 11694686. DOI: 10.14744/AnatolJCardiol.2024.4746.

Reproducibility and Predictive Value of White-Coat Hypertension in Young to Middle-Age Subjects.

Palatini P, Mos L, Saladini F, Vriz O, Fania C, Ermolao A Diagnostics (Basel). 2023; 13(3).

PMID: 36766538 PMC: 9914311. DOI: 10.3390/diagnostics13030434.

Impact of Uncontrolled Hypertension at 3 Months After Intracerebral Hemorrhage.

Biffi A, Teo K, Castello J, Abramson J, Leung I, Leung W J Am Heart Assoc. 2021; 10(11):e020392.

PMID: 33998241 PMC: 8483505. DOI: 10.1161/JAHA.120.020392.

Hemodynamic Changes Associated With Transcervical Laryngeal Injection of Botulinum Toxin.

Hernandez B, Nagatsuka M, Wright Jr S, Marcellino A, Lovin B, Walker F J Voice. 2021; 37(3):452-455.

PMID: 33541763 PMC: 8325702. DOI: 10.1016/j.jvoice.2021.01.003.

Long-Term Risk of Progression to Sustained Hypertension in White-Coat Hypertension with Normal Night-Time Blood Pressure Values.

Faria J, Bastos J, Bertoquini S, Silva J, Polonia J Int J Hypertens. 2021; 2020:8817544.

PMID: 33489356 PMC: 7803260. DOI: 10.1155/2020/8817544.

References

Agyemang C, Bhopal R, Bruijnzeels M, Redekop W . Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis. Blood Press Monit. 2005; 10(5):243-8. DOI: 10.1097/01.mbp.0000172712.89910.e4. View

Staessen J, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K . Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit. 2002; 6(6):355-70. DOI: 10.1097/00126097-200112000-00016. View

Labinson P, Giacco S, Gift H, Mansoor G, White W . The importance of the clinical observer in the development of a white-coat effect in African-American patients with hypertension. Blood Press Monit. 2008; 13(3):139-42. DOI: 10.1097/MBP.0b013e3282f76713. View

Franklin S, Thijs L, Asayama K, Li Y, Hansen T, Boggia J . The Cardiovascular Risk of White-Coat Hypertension. J Am Coll Cardiol. 2016; 68(19):2033-2043. DOI: 10.1016/j.jacc.2016.08.035. View

Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D . White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016; 34(4):593-9. DOI: 10.1097/HJH.0000000000000832. View

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M . 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2013; 23(1):3-16. DOI: 10.3109/08037051.2014.868629. View

Siegel W, Blumenthal J, Divine G . Physiological, psychological, and behavioral factors and white coat hypertension. Hypertension. 1990; 16(2):140-6. DOI: 10.1161/01.hyp.16.2.140. View

Kleinert H, Harshfield G, Pickering T, Devereux R, Sullivan P, Marion R . What is the value of home blood pressure measurement in patients with mild hypertension?. Hypertension. 1984; 6(4):574-8. DOI: 10.1161/01.hyp.6.4.574. View

Mancia G, Facchetti R, Parati G, Zanchetti A . Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension. 2014; 64(6):1388-98. DOI: 10.1161/HYPERTENSIONAHA.114.04278. View

10.

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

11.

Pickering T, James G, Boddie C, Harshfield G, Blank S, LARAGH J . How common is white coat hypertension?. JAMA. 1988; 259(2):225-8. View

12.

Manios E, Koroboki E, Tsivgoulis G, Spengos K, Spiliopoulou I, Brodie F . Factors influencing white-coat effect. Am J Hypertens. 2008; 21(2):153-8. DOI: 10.1038/ajh.2007.43. View

13.

Fagard R, Staessen J, Thijs L, Bulpitt C, Clement D, de Leeuw P . Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. J Hypertens. 2004; 22(1):81-7. DOI: 10.1097/00004872-200401000-00016. View

14.

Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H . Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009; 54(2):226-32. DOI: 10.1161/HYPERTENSIONAHA.109.129882. View

15.

Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J . Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005; 46(3):508-15. DOI: 10.1016/j.jacc.2005.03.070. View

16.

Hermida R, Ayala D, Mojon A, Fernandez J . Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011; 34(6):1270-6. PMC: 3114338. DOI: 10.2337/dc11-0297. View

17.

OBrien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G . European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013; 31(9):1731-68. DOI: 10.1097/HJH.0b013e328363e964. View

18.

Siven S, Niiranen T, Kantola I, Jula A . White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study. J Hypertens. 2015; 34(1):54-60. DOI: 10.1097/HJH.0000000000000750. View

19.

Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs F . Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011; 378(9798):1219-30. DOI: 10.1016/S0140-6736(11)61184-7. View

20.

Fagard R, Cornelissen V . Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007; 25(11):2193-8. DOI: 10.1097/HJH.0b013e3282ef6185. View